References
- Auw-Haedrich C, Coupland S, Kapp A, Schmitt-Graff A, Buchen R, Witschel H. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Br J Ophthalmol 2001; 85:63–69.
- Eckardt AM, Lemound J, Rana M, Gellrich NC. Orbital lymphoma: diagnostic approach and treatment outcome. World J Surg Oncol 2013; 11:1–6.
- Dias JS, Dittrich MA, Sousa JM, Teixeira LF, Manso PG. Medial rectus muscle myositis as an atypical presentation of mucosa-associated lymphatic tissue lymphoma: a case report. Arq Bras Oftalmol 2014; 77:116–118.
- Ponzoni M, Govi S, Licata G, Mappa S, Giordano Resti A, Politi LS, et al. A reappraisal of the diagnostics and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma. Oncologist 2013; 18:876–884.
- Galieni P, Polito E, Leccisotti A, Marotta G, Lasi S, Bigazzi C, et al. Localized orbital lymphoma. Haematologica 1997; 82:436–439.
- Graf SA, Gopal AK. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. Hematology Am Soc Hematol Educ Pogram 2014; 1:151–157.
- Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125:1236–1243.
- Siddiqi T, Thomas SH, Chen R. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenomics Pers Med 2014; 7:79–85.